CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $10.47B, above the global median of $1.15B
- PositionDebt-to-equity is 2.31×, higher than 95% of its Biotechnology peers (median 0.19×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
10.47BUSDvs all stocks (USD)
Revenue (TTM)
622.01MUSDvs all stocks (USD)
Profit Margin
-48.38%vs Biotechnology peers
Beta
1.26xvs all stocks
52-Week Change
405.10%vs all stocks
Market Capitalization
10.47BUSDvs all stocks (USD)
Enterprise Value
9.70BUSDvs all stocks (USD)
Forward P/E
-15.88xvs Biotechnology peers
Price to Sales (TTM)
16.35xvs Biotechnology peers
Price to Book (MRQ)
16.52xvs Biotechnology peers
Enterprise to Revenue
15.60xvs Biotechnology peers
Enterprise to EBITDA
-49.37xvs Biotechnology peers
Profit Margin
-48.38%vs Biotechnology peers
Operating Margin
-191.57%vs Biotechnology peers
Return on Assets (TTM)
-7.22%vs Biotechnology peers
Return on Equity (TTM)
-42.37%vs Biotechnology peers
Revenue (TTM)
622.01MUSDvs all stocks (USD)
Revenue per Share (TTM)
4.47USDUpdated Jul 18, 2026Quarterly Revenue Growth
-86.40%vs Biotechnology peers
Gross Profit (TTM)
622.01MUSDvs all stocks (USD)
EBITDA (TTM)
164.82MUSDvs all stocks (USD)
Net Income (TTM)
-300.91MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-86.41%vs Biotechnology peers
Operating Cash Flow (TTM)
-36.31MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-46.12MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
37.36MUSDFY2025 · Sep 30, 2025Revenue
829.45MUSDFY2025 · Sep 30, 2025Operating Income
98.35MUSDvs all stocks (USD)
Pre-tax Income
51.53MUSDFY2025 · Sep 30, 2025Income Tax Expense
21.42MUSDFY2025 · Sep 30, 2025Net Income
30.11MUSDFY2025 · Sep 30, 2025EBIT
140.89MUSDFY2025 · Sep 30, 2025EBITDA (Income Statement)
164.82MUSDFY2025 · Sep 30, 2025Research & Development
607.16MUSDFY2025 · Sep 30, 2025Selling, General & Administrative
121.92MUSDFY2025 · Sep 30, 2025Non-operating Interest Income
37.29MUSDFY2025 · Sep 30, 2025Non-operating Interest Expense
89.36MUSDFY2025 · Sep 30, 2025EPS (Basic)
-0.0100USDFY2025 · Sep 30, 2025EPS (Diluted)
-0.0100USDFY2025 · Sep 30, 2025Basic Shares Outstanding
133.76MSharesFY2025 · Sep 30, 2025Diluted Shares Outstanding
133.76MSharesFY2025 · Sep 30, 2025Net Income from Continuing Operations
30.11MUSDFY2025 · Sep 30, 2025Minority Interests (P&L)
-31.75MUSDFY2025 · Sep 30, 2025Operating Cash Flow
156.98MUSDFY2025 · Sep 30, 2025Free Cash Flow
134.31MUSDFY2025 · Sep 30, 2025Cash & Cash Equivalents (End of Period)
226.55MUSDFY2025 · Sep 30, 2025Interest Paid
19.00KUSDFY2025 · Sep 30, 2025Starting Profit (CF Statement)
30.11MUSDFY2025 · Sep 30, 2025Depreciation & Amortization
23.93MUSDFY2025 · Sep 30, 2025Stock-based Compensation
63.37MUSDFY2025 · Sep 30, 2025Other Non-cash Items
89.36MUSDFY2025 · Sep 30, 2025Change in Accounts Receivable (CF)
-56.97MUSDFY2025 · Sep 30, 2025Change in Accounts Payable (CF)
6.29MUSDFY2025 · Sep 30, 2025Change in Other Assets/Liabilities
888.00KUSDFY2025 · Sep 30, 2025Capital Expenditures
-22.67MUSDFY2025 · Sep 30, 2025Purchase of Investments
-796.26MUSDFY2025 · Sep 30, 2025Sale of Investments
689.63MUSDFY2025 · Sep 30, 2025Net Investing Cash Flow
-129.29MUSDFY2025 · Sep 30, 2025Long-term Debt Issuance
0.00USDFY2025 · Sep 30, 2025Long-term Debt Payments
-201.63MUSDFY2025 · Sep 30, 2025Net Short-term Debt Issuance
10.26MUSDFY2025 · Sep 30, 2025Other Financing Charges
-5.00MUSDFY2025 · Sep 30, 2025Net Financing Cash Flow
45.02MUSDFY2025 · Sep 30, 2025Shares Outstanding
140.57MSharesUpdated Jul 18, 2026Float Shares
122.78MSharesUpdated Jul 18, 2026Shares Short
8.43MSharesUpdated Jul 18, 2026Short Ratio
3.25daysvs all stocks
Short % of Shares Outstanding
8.34%vs all stocks
% Held by Insiders
3.68%vs all stocks
% Held by Institutions
88.91%vs all stocks
Total Cash (MRQ)
1.78BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
12.65USDUpdated Jul 18, 2026Total Debt (MRQ)
1.38BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
2.31xvs Biotechnology peers
Current Ratio (MRQ)
6.23xvs Biotechnology peers
Book Value per Share (MRQ)
4.37USDUpdated Jul 18, 2026Total Assets
1.39BUSDvs all stocks (USD)
Total Current Assets
950.64MUSDFY2025 · Sep 30, 2025Total Liabilities
881.88MUSDFY2025 · Sep 30, 2025Total Non-current Assets
434.66MUSDFY2025 · Sep 30, 2025Total Non-current Liabilities
686.39MUSDFY2025 · Sep 30, 2025Total Current Liabilities
195.49MUSDFY2025 · Sep 30, 2025Cash & Cash Equivalents
88.71MUSDFY2025 · Sep 30, 2025Other Short-term Investments
830.66MUSDFY2025 · Sep 30, 2025Accounts Receivable
6.82MUSDFY2025 · Sep 30, 2025Accounts Payable
17.67MUSDFY2025 · Sep 30, 2025Short-term Debt
47.29MUSDFY2025 · Sep 30, 2025Deferred Revenue
2.40MUSDFY2025 · Sep 30, 2025Other Current Liabilities
10.81MUSDFY2025 · Sep 30, 2025Long-term Debt
319.00MUSDFY2025 · Sep 30, 2025Common Stock (Book)
231.00KUSDFY2025 · Sep 30, 2025Retained Earnings
-1.63BUSDFY2025 · Sep 30, 2025Total Shareholders' Equity
503.42MUSDvs all stocks (USD)
Treasury Stock
53.19MUSDFY2025 · Sep 30, 202552-Week Low
14.30USDUpdated Jul 18, 202652-Week High
87.83USDUpdated Jul 18, 202652-Week Change
405.10%vs all stocks
Beta
1.26xvs all stocks
50-Day MA
77.51USDUpdated Jul 18, 2026200-Day MA
62.40USDUpdated Jul 18, 2026Avg 10-Day Volume
1.83MSharesUpdated Jul 18, 2026Avg 30-Day Volume
2.35MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-2.27USDUpdated Jul 18, 2026Other Income / Expense
5.26MUSDFY2025 · Sep 30, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 2.31×, higher than 95% of its Biotechnology peers (median 0.19×)Significant
Debt-to-equity: 2.31Industry median: 0.19Industry P95: 1.58Peers compared: 24.00
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 16.35Revenue Growth YoY: -0.86
Significant cash reserves alongside high leverageNotable
Cash (USD): 1,782,190,976Total Debt (USD): 1,383,788,032Debt-to-Equity: 2.31
Financial Health
Altman Z-Score 7.06: safe zoneNotable
Altman Z-Score: 7.06
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $10.47B, above the global median of $1.15BNotable
Market cap (USD): 10,465,676,660Global Median: 1,146,734,693.424
Revenue is $622.01M, above the global median of $520.53MNotable
Revenue (USD): 622,009,024Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Krystal Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRule
Globus Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
RemeGen Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Lupin Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dr. Reddy's Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Summit Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abivax SA
Tier 1ProductionApproval-Gated PipelineRule
Laurus Labs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Apogee Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cytokinetics, Incorporated
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
RR Kabel Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Puma Biotechnology Inc.
2 interpretationsFCF Ratios ElevatedIndustry-Benchmarked Return on Capital Elevated
Travere Therapeutics Inc.
1 interpretationIndustry-Benchmarked Return on Capital Elevated